ClinicalTrials.gg
RecruitingNCT06752720RAINBOW-2aUpdated Jan 24, 2025

Intracerebral Autologous Stem Cell Therapy for Chronic Stroke Patients

A Phase 2 interventional study of Stem cell Transplantation in Stroke, Stroke, Ischemic and Stroke; Sequelae, sponsored by Hokkaido University Hospital. Recruiting at 1 site in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-24.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's listed conditions name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hokkaido University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Ischemic Stroke with a site in Japan — 7 open to participants now, 11 under way, 3 of them phase 3. Ischemic Stroke · Japan.

Planned enrollment
35th of 35
8 · median 270
Started
2024
the only one that year
Phase 2
8 of 43
2 open now
Primary completion
2025-12
later than 0 of 10 live
Registered
37th of 43
by date

Among the 43 studies in Ischemic Stroke with a site in Japan, this one is the 35th largest by planned enrollment of the 35 interventional ones that give a count, is the only one that started in 2024, is one of 8 in phase 2, reaches primary completion later than 0 of the 10 other live ones, and was the 37th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

7 of the 43 studies in Ischemic Stroke with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Ischemic Stroke with a site in Japan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate if autologous mesenchymal stem cell (HUNS001-01) transplantation therapy can provide neurological recovery in patients with chronic stage of stroke resulting in moderate to severe neurological sequelae. The main questions it aims to answer are:

Can HUNS001-01 intracerebral transplantation demonstrate improvement in the mRS of disability for 1 year after intervention? Can HUNS001-01 intracerebral transplantation can be performed without any adverse events for 1 year after intervention?

Participants will receive the below interventions.

  • Screening for the eligibility to enroll the clinical trial (interview, blood test, imaging)
  • Harvest of platelet concentrates (PC)
  • Harvest of bone marrows (BM)
  • Receive intracerebral transplantation surgery of HUNS001-01
  • Post-operative rehabilitation
  • Follow-up studies (until 1 year or termination of the trial)
03

Conditions studied

  • Stroke
  • Stroke, Ischemic
  • Stroke; Sequelae

Browse trials for

Keywords

  • stem cell therapy
  • mesenchymal stem cell
  • ischemic stroke
  • chronic
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 8 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Hokkaido University Hospital is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 20 and 70 years
  2. Clinical diagnosis of ischemic stroke between 6 months and 5 years ago
  3. Ischemic area in the territory of unilateral interanal cerebral artery
  4. Moderate to severe neurological symptoms; mRS 3 or 4, and Brunnstrom stage Ⅲ or IV
  5. Subjects with a DTI-RAINBOW (R-DTI) value of more than 70% at screening MR imaging
  6. No significant neurological impairment before the stroke (Pre-stroke mRS of 0 or 1)
  7. Subjects who can give by its self

Exclusion criteria

Exclusion criteria

  1. Subject showing severe lower extremity contracture (Maximum knee extension less than -15 degrees, Maximum ankle flexion less than 0 degree)"
  2. Anaemia (Hg \< 10·0 g/dL)
  3. Thrombocytopaenia ( count \< 100,000/mm3)
  4. Severe heart disease (ischaemic heart disease, heart failure)
  5. Severe Systemic organ failure \<3·0× Total \< 1·5× upper limit of normal Serum creatinine \< 1·5× upper limit of normal
  6. History of
  7. Carriers of infectious disease: syphilis, , , -1/HIV-2, HTLV-1, parvovirus B19
  8. Pregnant or lactating or expecting to become pregnant during the study
  9. Known serious allergy to any agents used in the study
  10. for magnetic resonance imaging
  11. History of seizure within 2 years
  12. Subject's body weight less than 45 kg for male and 40kg for female "13. Participating in another clinical trial within 90 days, or planning to participate in another clinical trial in the future"
  1. Any condition that in the judgement of the investigator would place the patient at undue risk
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Stem cell transplantation

    Intracerbral transplantation of autologous mescenchymal stem cells (HUNS001-01, 4 x 10\^7 MSC cells)

    Drug: Stem cell Transplantation

Interventions

  • DrugStem cell Transplantation

    Manufactured autologous mescenchymal stem cell (HUNS001-01) in our cell processing center will be injected into the brain, totally 4 x 10\^7 cells, in 2 brain sites.

07

What researchers measure

Primary outcomes

  1. Efficacy of HUNS001-01 administration

    The frequency of the improvement in mRS of disability by 1 or more from baseline

    Time frame: one year

Secondary outcomes

  1. Safety of HUNS001-01 administration

    frequency of Adverse Event

    Time frame: one year

  2. Change in NIHSS examination

    Mean improvement of NIHSS (0-42, higher score means worse outcome)

    Time frame: one year

  3. Change in FIM examination

    Mean improvement of FIM (18-126, higher score means better outcome)

    Time frame: one year

  4. Change in Fugl-Myer examination

    Mean improvement of Fugl-Myer (0-226, higher score means better outcome)

    Time frame: one year

  5. Change in Barthal index examination

    Mean improvement of Barthal index (0-100, higher score means better outcome)

    Time frame: one year

  6. Change in FDG-PET examination

    Mean improvement of FDG-PET set for ipsilateral motor cortex

    Time frame: one year

  7. Change in IMZ-SPECT examination

    Mean improvement of IMZ-SPECT set for ipsilateral motor cortex

    Time frame: one year

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 12 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Dec 31, 2024
StartActual
Dec 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Nov 30, 2027
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06752720
Lead sponsor
Hokkaido University Hospital
Collaborators
RAINBOW Inc.
Responsible party
Sponsor
First posted
Dec 31, 2024
Start date
Dec 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Jan 24, 2025

Study contacts

Kota Kurisu, M.D., Ph.D.
Contact
kkurisu0912@gmail.com
+81-11-706-1161 ext. 5987

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion